A New Horizon for Essential Tremor: Praxis's Ulixacaltamide Earns Breakthrough Status
A Biotech Bombshell: Praxis Precision Medicines Reels from Culper Research's Damning Report
Praxis Precision Medicines Stock Plummets Following Brutal Short-Seller Attack from Culper Research